根治性术前分期可提高切除的肾上腺寡转移非小细胞肺癌患者的生存率：一项多中心研究。
Exhaustive preoperative staging increases survival in resected adrenal oligometastatic non-small-cell lung cancer: a multicentre study.
机构信息
Department of Thoracic Surgery, Calmette Hospital, University Hospital of Lille, Lille, France.
Department of Thoracic Surgery, Foch Hospital, Suresnes, France.
出版信息
Eur J Cardiothorac Surg. 2017 Oct 1;52(4):698-703. doi: 10.1093/ejcts/ezx193.
OBJECTIVES
Adrenal oligometastatic non-small-cell lung cancer is rare, and surgical management remains controversial.
METHODS
We performed a multicentre, retrospective study from January 2004 to December 2014. The main objective was to evaluate survival in patients who had undergone adrenalectomy after resection of primary lung cancer. Secondary objectives were to determine prognostic, survival and recurrence factors.
RESULTS
Fifty-nine patients were included. Forty-six patients (78%) were men. The median age was 58 years [39-75 years]. Twenty-six cases (44%) showed synchronous presentation, and 33 cases (56%) had a metachronous presentation. The median time to onset of metastasis was 18.3 months [6-105 months]. The 5-year overall survival rate was 59%; the median survival time was 77 months [0.6-123 months]. A recurrence was observed in 70% of the population. Mediastinal lymph node invasion (P = 0.035) is a detrimental prognostic factor of survival.
CONCLUSIONS
After exhaustive staging, patients with adrenal oligometastatic non-small-cell lung cancer benefit from bifocal surgery.
目的
肾上腺寡转移非小细胞肺癌较为罕见，其外科治疗仍存在争议。
方法
我们开展了一项 2004 年 1 月至 2014 年 12 月的多中心回顾性研究。主要目的是评估肺癌切除术后行肾上腺切除术患者的生存情况。次要目的是确定预后、生存和复发的相关因素。
结果
共纳入 59 例患者，其中 46 例（78%）为男性，中位年龄为 58 岁[39-75 岁]。26 例（44%）为同时性病变，33 例（56%）为异时性病变。转移的中位时间为 18.3 个月[6-105 个月]。5 年总生存率为 59%；中位生存时间为 77 个月[0.6-123 个月]。70%的患者出现复发。纵隔淋巴结侵犯（P=0.035）是生存的不利预后因素。
结论
在进行详尽分期后，肾上腺寡转移非小细胞肺癌患者可从双焦点手术中获益。
Zotero 插件